Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

drug-induced methemoglobinemia - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

drug-induced methemoglobinemia

MONDO:0018740

Also known as:acquired methemoglobinemia

Overview

Methemoglobinemia that is caused by exposure to certain drugs (xylocaine and benzene).

Treatments1 FDA approved

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Methemoglobinemia; and common findings: Anxiety, Cyanosis, Confusion, and Acidosis and others. 21 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	4	Anxiety, Headache, Fatigue

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for drug-induced methemoglobinemia, including METHYLENE BLUE (PROVAYBLUE, approved 2016).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 1 very common feature, 11 common features.

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for drug-induced methemoglobinemia.

39 publications have been identified in PubMed for drug-induced methemoglobinemia. Research spans Case Report / Case Series (82%), Epidemiology / Natural History (8%), and Other (5%).

Research Type	Count	% of Total
Patient case studies	32	82%

Data assembled from 5 of 12 sources · Last updated Oct 3, 2026, 8:13 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:464453

GARD

Genetic and Rare Diseases Info Center

GARD:21930

Questions for Your Care Team

→What are the benefits and potential side effects of PROVAYBLUE for managing drug-induced methemoglobinemia?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

drug-induced methemoglobinemia

Overview

Clinical Presentation

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

drug-induced methemoglobinemia

Overview

Clinical Presentation

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications